acterised by heightened immune processes at Background -Mediators released by al-the site of disease activity. 1 In particular, an veolar macrophages, as well as by T cells, enhanced recruitment and activation of implay an important part in modulating local munocompetent cells (alveolar macrophages immune processes in sarcoidosis. Among and T cells) occurs within the alveolar strucalveolar macrophage secretory products, tures. Once activated, these cells have a wide arachidonic acid metabolites are known to spectrum of effector functions including seregulate inflammatory and immune re-cretion of various mediators that play an imactions. It has been suggested that cyclo-portant part in the evolution and modulation oxygenase and lipoxygenase pathway of local immune processes in sarcoidosis.
We hypothesised that an imbalance of according to the method previously described. 22 arachidonic acid metabolites released by al-Briefly, a fibreoptic bronchoscope was wedged veolar macrophages could occur in sarcoidosis in a segment of the middle lobe or lingula and and play a part in modulating the granu-150-200 ml of sterile saline solution (warmed lomatous response in this disease. To test this to 37°C) was injected in 20 ml aliquots and hypothesis we have investigated the capacity immediately recovered by gentle suction. BAL of alveolar macrophages to release PGE 2 and fluid was filtered through two layers of surgical leukotriene B 4 (LTB 4 ) in vitro from patients gauze to remove mucus and centrifuged at with sarcoidosis in different states of disease 400 g for 10 minutes at 4°C. The resulting activity and compared this with their release pellet was washed twice with phosphate by normal alveolar macrophages. buffered saline (PBS; Sigma Chemical, St Louis, Missouri, USA), resuspended in Hank's balanced salt solution (HBSS), and cells were Methods counted with an haemocytometer. The differ-  ential cell count was accomplished according Thirty two patients with sarcoidosis (18 men) to morphological criteria in cytocentrifuged of mean (SD) age 34.2 (9.18) years were stud-smears stained with May Grunwald-Giemsa. ied. The diagnosis of sarcoidosis was based on Alveolar macrophages were isolated by adconsistent clinical features and was confirmed herence procedures on plastic. Briefly, BAL by histopathological findings. Other granu-cells were resuspended in RPMI-1640 medium lomatous diseases were reliably excluded. Dis-(GIBCO Laboratories, Grand Island, New ease activity was evaluated according to the York, USA) containing 100 U/ml penicillin and consensus conference on disease activity in 100 g/ml streptomycin (complete medium) to sarcoidosis 21 -that is, on the basis of the achieve a concentration of 1×10 6 viable macrofollowing criteria: (1) clinical findings (recently phages per ml. An aliquot of 1 ml of the cell developed or progressing respiratory symptoms suspension was plated into each well of 24 such as cough and dyspnoea, or systemic symp-well plastic culture plates (Costar, Cambridge, toms such as fever, weight loss, severe fatigue, Massachusetts, USA) and cells were allowed or progressive changes on the chest radiograph to adhere for one hour at 37°C in 5% CO 2 . or deterioration of lung function within the last The cells were then washed three times with three months); (2) percentage of lymphocytes warm medium to remove non-adherent cells. and absolute number of T cells recovered from The resulting alveolar macrophage population the bronchoalveolar lavage (BAL) fluid; and was >95% pure on the basis of non-specific (3) 67-gallium citrate ( 67 Ga) scan positivity. esterase staining and >95% of the cells were According to all three 18 patients had active viable as judged by the trypan blue exclusion sarcoidosis and 14 patients were in the inactive test. Alveolar macrophages were then cultured phase of the disease. In the first group 10 in complete medium in the presence or absence patients were radiographic stage I and eight of opsonised zymosan (final concentration were stage II, and in the second group six were 500 g/ml) for varying periods of time. Control stage I and eight were stage II. Patients with cultures consisted of medium with or without active disease were newly diagnosed and had a opsonised zymosan incubated in the absence mean disease duration of 3.9 (0.8) months at of alveolar macrophages for the same time the time of admission to the study. All had periods and processed identically. The viability evidence of clinical deterioration defined as of adherent macrophages was assessed by the worsening of respiratory symptoms or protrypan blue exclusion test at the end of each gressive changes on the chest radiograph, or experiment and was found to be at least 90%. deterioration of lung function. In contrast,
The monolayer supernatants were collected, patients with inactive disease had a mean discentrifuged at 3000 g for five minutes and ease duration of 2.5 (0.6) years and follow up frozen at −80°C for later analysis of PGE 2 and visits during the year prior to admission to the LTB 4 . study showed a clinically stable disease in the To evaluate the kinetics of PGE 2 and LTB 4 absence of steroid treatment -that is, no resrelease, alveolar macrophage supernatants were piratory symptoms, no progressive changes on harvested at 0, 30, 60, 120 minutes and 24 the chest radiograph or deterioration of lung hours of culture. Because of the high number function. All patients studied were nonof cells required, this analysis was carried out smokers and none had received steroids or in only a limited number of subjects (four non-steroidal anti-inflammatory agents in the controls and five each with non-active and previous three months. Ten normal non-smokactive sarcoidosis). ing volunteers (six men) of mean age 39.2 (9)
As the kinetics of LTB 4 release by unyears acted as controls. All were asymptomatic stimulated alveolar macrophages showed that with normal chest radiographs and pulmonary higher levels of the hydroxyacid were produced function. None had recently received any drug.
during the early stages of culture with a tendThe study conformed to the Declaration of ency to decrease over the next 24 hours, in Helsinki and informed consent was obtained some experiments their ability to metabolise from each subject. 4 Supernatants from alveolar macrophages time period.
Finally, in some experiments the effect of (1 ml) were extracted using a solid phase cartridge (Supelclean C18 hydroxide) and analysed using a gradient pump Solid phase EIA was performed by using spe-system (Beckman mod.168). UV absorbance cialised Titertek microtitration equipment, in-was monitored at 235 nm and 280 nm, and full cluding an automatic plate washer (Microplate UV spectra (210-340 nm) were acquired at a Washer 120), an automatic dispenser (Auto-rate of 0.5 Hz. A multilinear gradient from drop), and a spectrophotometer (Multiskan solvent A to solvent B (50% methanol, 50% MC) from Flow Laboratories (Helsinki, Fin-acetonitrile) was used. A semi-micro column land). Microtitre plates were from Nunc (Den-(Superspher 15×0.2 cm, 4 m particle size, mark). For the quantitative determination Merck, Darmstadt, Germany) was used at a mouse monoclonal anti-rabbit IgG antibody flow rate of 0.25 ml/min to increase the sensiwas immobilised on 96 well microtitre plates tivity of the analysis. This method allowed by dispensing 200 l of a 10 g/ml anti-IgG easy separation of LTB 4 from both 5S,12S-solution (phosphate buffer 5×10 −2 M, pH 7.4, dihydroxyeicosatetraenoic acid (5S,12S-dicontaining 2% glutaraldehyde) automatically HETE) and 6 trans LTB 4 epimers, with a into each well using the Autodrop apparatus.
lower detection limit for positive identification After overnight incubation (at least 18 hours) through UV spectral analysis of chromatoat room temperature, 100 l of buffer (NaN 3 graphic peaks of 3 pmol LTB 4 . Synthetic stand-0.03% w/v, NaCl 0.4 M, EDTA 1 mM, BSA ards were used to determine daily retention 0.3% w/v, in phosphate buffer 0.1 M, pH 7.4) time of arachidonic acid metabolites (Cascade was added and the plates stored at 4°C for 24 Biochem., Reading, UK). hours prior to use. The plates were then washed with 0.01 M phosphate buffer, pH 7.4, containing 0.05% v/v Tween 20. The assay was performed in EIA buffer (0.1 M phosphate COX activity in the supernatant of alveolar buffer, pH 7.4, containing 0.4 M NaCl, 1 mM macrophages EDTA, 0.01% BSA and 0.07% NaN 3 ), total Alveolar macrophages were cultured at a densvolume 150 l. Each component was added in a ity of 1×10 6 /ml in RPMI containing 100 U/ml volume of 50 l: standard or biological sample, penicillin and 100 mg/ml streptomycin, in the enzymatic tracer and specific antiserum (final presence or absence of opsonised zymosan, for dilutions of 1:60 000 and 1:40 000, respectively, varying periods of time. One hour before the for LTB 4 and PGE 2 ). After overnight incubation end of the incubation period 14 C-arachidonic at 4°C the plates were washed and 200 l of acid (0.5 Ci) was added for evaluation of its Ellman's reagent, consisting of enzymatic conversion rate to COX products. The supersubstrate (acetylthiocholine, 7.5×10 −4 M) and natant, approximately 1 ml, was collected, 1 ml chromogen (5,5′-dithiobis-(2-nitro-benzoic ethanol was added, and the mixture was kept acid), 5×10
−4 M) in 0.01 M phosphate buffer, at −20°C until HPLC analysis. Samples were was automatically dispensed into each well with thawed, acidified by adding 10 l formic acid the Autodrop. After three hours the absorbance (18.5 N), and centrifuged at 2500 g for 15 minat 414 nm was measured. In order to evaluate utes at room temperature. The supernatant the concentration of LTB 4 and PGE 2 in bio-(approximately 1.8 ml) was diluted with 4 ml logical samples a standard curve was used from ultrapure water (Millipore MilliQ, fed with 7.8 pg/ml to 1 ng/ml. Standard curves and bio-bi-distilled water) and loaded onto BondElut logical samples were analysed with an IBM cartridge (Varian, Milan, Italy) which had been computer using a linear log-logit trans-previously activated with 3 ml methanol and formation. The intra-assay coefficient of vari-3 ml ultrapure water. Samples were then ation ranged between 14% and 29% for LTB 4 washed with 4 ml water followed by 6 ml petand between 6% and 15% for PGE 2 .
roleum ether to get rid of any residue of water; Results are expressed in terms of percentage elution was performed with 5 ml ethyl acetate. B/B 0 where B and B 0 represent the absorbance The organic phase was taken to dryness and measured on the bound fraction in the presence redissolved using 0.6 ml of a 1:2 mixture of or absence of eicosanoid competitors, re-methanol:water. The samples were then inspectively.
jected into a Beckman Gold HPLC equipped with a reverse phase column (LiChroCart RP-18, 250×4 mm, 5 m particles, Merck-Bracco,     () Milan, Italy) connected to a radioactivity detector (Ramona-Raytest, Straubenhardt, GerThe identity of both LTB 4 and PGE 2 was checked in representative samples (three many; liquid scintillator FloScint-V Packard, flow 3 ml/min, liquid scintillator cell 0.8 ml). patients with sarcoidosis and three control subjects) by combined HPLC-EIA coupled with Elution was carried out at a flow rate of 1 ml/ min using a multilinear gradient from solvent UV detection. A (ultrapure water with 0.1% acetic acid, v/v) and those with sarcoidosis. After zymosan stimulation a significant increase in PGE 2 reto solvent B (acetonitrile with 0.1% acetic acid, v/v).
lease was observed in both normal cells and those from patients with sarcoidosis (p<0.05 and p<0.001, respectively, compared with unstimulated cells). No significant differences in   Statistical analysis was performed using the PGE 2 release by either unstimulated or stimulated alveolar macrophages were seen between Dunn test 25 for the comparison of the three groups and a paired Student's t test for within the groups.
The kinetics of LTB 4 release by unstimulated group comparisons. Data are expressed as mean (SE). alveolar macrophages showed that higher levels of the hydroxyacid were produced during the early stages of culture (30-120 minutes) in both normal cells and those from patients with Results    sarcoidosis, with a tendency to decrease over the next 24 hours; this decrease, however, was The total cell recovery, percentage of lymphocytes, and the absolute number of lym-statistically significant only for normal alveolar macrophages (fig lA) . The analysis of some phocytes were found to be significantly increased in the BAL fluid of patients with active sarcoidosis compared with the corresponding values obtained from both patients with inactive disease and control subjects (in both cases p<0.001; table 1). The absolute number of alveolar macrophages was also significantly greater in the BAL fluid of patients with active sarcoidosis compared with that of both patients with inactive disease (p<0.01) and control subjects (p<0.05).
 
Both PGE 2 and LTB 4 were undetectable in supernatants from cell free incubations or from cells at time zero. The time course of PGE 2 release by unstimulated alveolar macrophages showed detectable levels only after 24 hours of culture and a similar profile was observed in stimulated alveolar macrophages (data not shown).
PGE 2 levels produced after 24 hours of culture by both unstimulated and zymosan stimulated alveolar macrophages from the overall population of patients with sarcoidosis and normal subjects are shown in table 2. Under resting conditions low levels of the eicosanoid were produced by cells from both normal subjects levels at 24 hours was due to adherence of the product to the surfaces of the culture well. After zymosan stimulation the kinetics of LTB 4 release showed a different behaviour in normal cells and those from patients with sarcoidosis, sarcoidosis, 0.61 (0.17) ng/10 6 cells; active sarcoidosis, 0.56 (0.19) ng/10 6 cells) and no with normal cells producing similar levels of the hydroxyacid during the early and late times differences were observed between the groups. Stimulated alveolar macrophages from patients of culture while LTB 4 release markedly increased after 60 minutes of culture in cells from with active sarcoidosis were still found to produce significantly higher levels of LTB 4 than patients with active sarcoidosis, remaining at a high level for 24 hours ( fig 1B) . 6 cells, p<0.05), whereas no significant differences were observed between stimulated alveolar macrophages from the overall population studied are shown. Only minute LTB 4 levels released by alveolar macrophages from patients with inactive disease (6.01 amounts of the hydroxyacid were produced during resting conditions by both normal cells (2.44) ng/10 6 cells) and normal subjects. In order to evaluate whether cyclo-oxygenase and those from patients with sarcoidosis. Zymosan stimulation induced a significant in-pathway inhibition could affect LTB 4 release by alveolar macrophages from patients with crease in LTB 4 release in alveolar macrophages from both normal subjects and patients with sarcoidosis, in some experiments indomethacin (3×10 −6 M) was added to cultured cells 30 sarcoidosis (p<0.05 and p<0.01, respectively, compared with unstimulated cells).
minutes before the addition of opsonised zymosan. As expected, in the presence of indoNo differences were observed during resting conditions in the levels of LTB 4 released by methacin no detectable synthesis of PGE 2 was observed, even after zymosan stimulation; cells from the three groups, but after zymosan stimulation alveolar macrophages from patients moreover, no significant effect was observed on LTB 4 release (fig 3) . These results suggest with active sarcoidosis released significantly higher amounts of LTB 4 than those from con-that, in the presence of indomethacin, stimulation with zymosan of alveolar macrophages trol subjects (p<0.05). The same behaviour was observed after 24 hours of culture when, from patients with sarcoidosis resulted in almost complete inhibition of the release of cycloin fact, basal LTB 4 levels produced by alveolar macrophages from all three groups were low oxygenase products and no shunting through the lipoxygenase pathway. (controls, 0.50 (0.13) ng/10 6 cells; non-active group.bmj.com on May 2, 2017 -Published by http://thorax.bmj.com/ Downloaded from Discussion increased levels of LTB 4 occurring in the inflammatory environment in patients with active This study shows that stimulated alveolar macrophages from patients with active sar-sarcoidosis might contribute to the locally heightened immune response. coidosis release significantly higher levels of LTB 4 than normal alveolar macrophages, sugOur study also showed different kinetics of release of cyclo-oxygenase and lipoxygenase gesting that alveolar macrophages in the BAL fluid of these patients are primed to release metabolites by resting alveolar macrophages.
Whereas PGE 2 levels were undetectable in the LTB 4 . In contrast, no differences were observed in PGE 2 release between normal cells and those early stages of culture, increasing only at 24 hours, LTB 4 levels were higher during the first from patients with sarcoidosis. Our observations are consistent with previous results hours of culture with a trend to decrease over the next 24 hours. This pattern is consistent showing that stimulated alveolar macrophages from rabbits immunised with BCG released with previous reports of arachidonic acid metabolism by animal and human alveolar macrolarger amounts of LTB 4 than cells from nonimmunised rabbits while the release of prosta-phages. [29] [30] [31] The decrease in release of LTB 4 did not seem glandin was decreased, 26 but differ from those of Bachwich et al 6 who failed to detect an to be attributable to omega oxidation since analysis of some alveolar macrophage superincrease in LTB 4 production by alveolar macrophages from patients with sarcoidosis and ob-natants with [ 3 H]-LTB 4 by HPLC did not reveal omega hydroxy or omega carboxy-LTB 4 ; served a reduced capacity of these cells to produce arachidonic acid metabolites com-these findings are also consistent with previous observations.
29 [32] [33] [34] [35] pared with normal alveolar macrophages. Many explanations can account for these Interestingly, after zymosan stimulation different kinetic behaviour was observed bediscrepancies. Bachwich et al 6 evaluated lipoxygenase metabolism in a smaller number of tween normal cells and cells from patients with active sarcoidosis; whereas normal cells repatients, only two of whom had active disease, different culture conditions and a different leased similar levels of the hydroxyacid during the early and late times of culture, LTB 4 release stimulus were employed, and lipoxygenase metabolism was evaluated following the ad-by cells from patients with active sarcoidosis increased significantly after 60 minutes of culdition of exogenous arachidonate. Wide differences in the metabolism of exogenous versus ture, remaining increased until 24 hours. These results further support the hypothesis that alendogenous fatty acid in both resting and agonist stimulated cells have been described by veolar macrophages from patients with active sarcoidosis appear to be primed to release Peters-Golden et al 27 showing that, whereas leukotrienes (especially LTB 4 ) were major LTB 4 . The use of cyclo-oxygenase inhibitors resulted in almost complete inhibition of the products of endogenous arachidonic acid released by agonist stimulation, exogenous ar-release of cyclo-oxygenase products and no shunting through the lipoxygenase pathway in achidonate was metabolised predominantly to cyclo-oxygenase products and mono-HETE cells from patients with sarcoidosis.
Pulmonary sarcoidosis is a disorder charbut only minimally to leukotrienes.
In the present study only the monolayer acterised by a variety of enhanced immune and inflammatory processes localised in the lung. supernatants were analysed for LTB 4 and PGE 2 so the results only reflect the amounts of ei-Activated T lymphocytes and alveolar macrophages are present in increased numbers in cosanoid released by the cells and not the total alveolar macrophage production of these the alveoli of patients affected by this disease.
These cells interact by spontaneously releasing metabolites. To the best of our knowledge, no intracellular storage site for eicosanoids has large amounts of mediators, and these interactions appear to be crucial for the development been described and found to be of physiological relevance. Eicosanoids are synthesised "de of the granuloma. In this context, the enhancement of LTB 4 release by the alveolar novo" by the interaction of different stimuli with the cell membrane and diffuse im-macrophages from patients with active disease in response to a phagocytic stimulus is pomediately into the surrounding environment. However, Damon et al 28 recently observed no tentially relevant. LTB 4 is a 5-lipoxygenase product of arachidonic acid metabolism that significant differences in total LTB 4 levels produced by alveolar macrophages from healthy has potent chemotactic activity for polymorphonuclear and mononuclear leucocytes 5 36-39 subjects and from asthmatic patients, whereas intracellular LTB 4 levels were slightly higher and its release by alveolar macrophages in patients with sarcoidosis may play a part in the in the asthmatic patients. This suggests that differences in eicosanoid production between amplification of the granulomatous response by recruiting mononuclear phagocytes from the cells from different subjects are not always the same when the products are analysed in blood into the lung. Furthermore, even if the contribution of LTB 4 to the regulation of supernatants, after alcohol destruction of the cells, or a combination of the two. On the basis cellular immunity is complex, 17 some observations suggest that it might play an amplificatory of the results of the present study, we cannot therefore exclude the possibility that the in-part in the immune response. LTB 4 has been shown to enhance interleukin 1 (IL-1) procreased LTB 4 levels released by alveolar macrophages from patients with sarcoidosis do not duction by human monocytes 40 and to replace IL-2 mediated helper cell requirement for reflect an increase in the total production of the eicosanoid, but rather an increased transport interferon-(IFN-) production in the mouse spleen cell system. 41 In addition, Rolaacross the cell membrane. In any case, the group.bmj.com on May 2, 2017 -Published by http://thorax.bmj.com/ Downloaded from
